Earnings Beat: InnovAge Holding Corp. Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Models

Innovus Pharmaceuticals, Inc. -5.11%

Innovus Pharmaceuticals, Inc.

INNV

7.61

-5.11%

InnovAge Holding Corp. (NASDAQ:INNV) investors will be delighted, with the company turning in some strong numbers with its latest results. It was overall a positive result, with revenues beating expectations by 5.0% to hit US$240m. InnovAge Holding also reported a statutory profit of US$0.08, which was an impressive 101% above what the analysts had forecast. Following the result, the analysts have updated their earnings model, and it would be good to know whether they think there's been a strong change in the company's prospects, or if it's business as usual. We've gathered the most recent statutory forecasts to see whether the analysts have changed their earnings models, following these results.

earnings-and-revenue-growth
NasdaqGS:INNV Earnings and Revenue Growth February 6th 2026

Following last week's earnings report, InnovAge Holding's three analysts are forecasting 2026 revenues to be US$933.0m, approximately in line with the last 12 months. Statutory earnings per share are predicted to shoot up 395% to US$0.24. Yet prior to the latest earnings, the analysts had been anticipated revenues of US$930.3m and earnings per share (EPS) of US$0.22 in 2026. The analysts seems to have become more bullish on the business, judging by their new earnings per share estimates.

The consensus price target was unchanged at US$5.00, implying that the improved earnings outlook is not expected to have a long term impact on value creation for shareholders.

Taking a look at the bigger picture now, one of the ways we can understand these forecasts is to see how they compare to both past performance and industry growth estimates. We would highlight that InnovAge Holding's revenue growth is expected to slow, with the forecast 3.9% annualised growth rate until the end of 2026 being well below the historical 7.2% p.a. growth over the last five years. Compare this against other companies (with analyst forecasts) in the industry, which are in aggregate expected to see revenue growth of 4.9% annually. Factoring in the forecast slowdown in growth, it seems obvious that InnovAge Holding is also expected to grow slower than other industry participants.

The Bottom Line

The biggest takeaway for us is the consensus earnings per share upgrade, which suggests a clear improvement in sentiment around InnovAge Holding's earnings potential next year. On the plus side, there were no major changes to revenue estimates; although forecasts imply they will perform worse than the wider industry. There was no real change to the consensus price target, suggesting that the intrinsic value of the business has not undergone any major changes with the latest estimates.

Following on from that line of thought, we think that the long-term prospects of the business are much more relevant than next year's earnings. At Simply Wall St, we have a full range of analyst estimates for InnovAge Holding going out to 2028, and you can see them free on our platform here..

That said, it's still necessary to consider the ever-present spectre of investment risk. We've identified 3 warning signs with InnovAge Holding , and understanding them should be part of your investment process.